Published on | 4 months ago
Programmes Digital, Industry & SpaceThe HORIZON-SESAR-2025 calls are part of the Horizon Europe programme, aimed at funding projects that strengthen the European Digital Sky.
Coordinated by the SESAR 3 Joint Undertaking, they drive the transformation of the Air Traffic Management (ATM) system through disruptive technologies, advanced automation, and environmental solutions.
These calls seek not only to improve the efficiency of Europe’s airspace but also to reduce aviation’s environmental footprint, optimise air navigation services, and ensure a safe transition towards future air mobility.
The HORIZON-SESAR-2025 calls target:
Transnational cooperation is prioritised to strengthen the European Research Area in air traffic management and innovative air mobility.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space AI Continent Cybersecurity
The European Commission has opened a call for evidence to collect research and best practices on how to simplify its legislation, especially when it comes to data, cybersecurity and artificial intelligence (AI). This initiative is part of the Commission’s simplification agenda and efforts to create a more favourable business environment, by... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.